$128.92
1.61%
Downside
Day's Volatility :5.73%
Upside
4.18%
57.14%
Downside
52 Weeks Volatility :68.11%
Upside
25.59%
Period | Sarepta Therapeutics, Inc. | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | 4.54% | 5.1% | 0.0% |
6 Months | 6.74% | 4.9% | 0.0% |
1 Year | 5.67% | 16.6% | 0.0% |
3 Years | 64.08% | 13.2% | -22.3% |
Market Capitalization | 12.8B |
Book Value | $11.3 |
Earnings Per Share (EPS) | 0.75 |
PE Ratio | 178.36 |
PEG Ratio | 159.25 |
Wall Street Target Price | 188.73 |
Profit Margin | 3.14% |
Operating Margin TTM | -0.19% |
Return On Assets TTM | 0.73% |
Return On Equity TTM | 5.2% |
Revenue TTM | 1.5B |
Revenue Per Share TTM | 15.79 |
Quarterly Revenue Growth YOY | 38.9% |
Gross Profit TTM | -78.1M |
EBITDA | 77.8M |
Diluted Eps TTM | 0.75 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | 1.59 |
EPS Estimate Next Year | 11.23 |
EPS Estimate Current Quarter | 0.0 |
EPS Estimate Next Quarter | 0.99 |
What analysts predicted
Upside of 46.39%
FY18 | Y/Y Change | |
---|---|---|
Revenue | 301.0M | ↑ 94.74% |
Net Income | -361.9M | ↑ 614.01% |
Net Profit Margin | -120.22% | ↓ 87.43% |
FY19 | Y/Y Change | |
---|---|---|
Revenue | 380.8M | ↑ 26.51% |
Net Income | -715.1M | ↑ 97.58% |
Net Profit Margin | -187.77% | ↓ 67.55% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 540.1M | ↑ 41.82% |
Net Income | -554.1M | ↓ 22.51% |
Net Profit Margin | -102.6% | ↑ 85.17% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 701.9M | ↑ 29.96% |
Net Income | -418.8M | ↓ 24.43% |
Net Profit Margin | -59.66% | ↑ 42.94% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 933.0M | ↑ 32.93% |
Net Income | -703.5M | ↑ 67.99% |
Net Profit Margin | -75.4% | ↓ 15.74% |
FY23 | Y/Y Change | |
---|---|---|
Revenue | 1.2B | ↑ 33.26% |
Net Income | -536.0M | ↓ 23.81% |
Net Profit Margin | -43.11% | ↑ 32.29% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 253.5M | ↓ 1.91% |
Net Income | -516.8M | ↑ 373.03% |
Net Profit Margin | -203.85% | ↓ 161.58% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 261.2M | ↑ 3.05% |
Net Income | -23.9M | ↓ 95.37% |
Net Profit Margin | -9.16% | ↑ 194.69% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 331.8M | ↑ 27.02% |
Net Income | -40.9M | ↑ 71.0% |
Net Profit Margin | -12.34% | ↓ 3.18% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Revenue | 396.8M | ↑ 19.58% |
Net Income | 45.7M | ↓ 211.53% |
Net Profit Margin | 11.51% | ↑ 23.85% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Revenue | 413.5M | ↑ 4.2% |
Net Income | 36.1M | ↓ 20.89% |
Net Profit Margin | 8.74% | ↓ 2.77% |
Q2 FY24 | Q/Q Change | |
---|---|---|
Revenue | 362.9M | ↓ 12.22% |
Net Income | 6.5M | ↓ 82.11% |
Net Profit Margin | 1.78% | ↓ 6.96% |
FY18 | Y/Y Change | |
---|---|---|
Total Assets | 1.6B | ↑ 25.54% |
Total Liabilities | 609.8M | ↑ 17.55% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 1.8B | ↑ 11.01% |
Total Liabilities | 1.0B | ↑ 64.75% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 3.0B | ↑ 63.74% |
Total Liabilities | 2.2B | ↑ 121.27% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 3.1B | ↑ 5.47% |
Total Liabilities | 2.2B | ↓ 0.13% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 3.1B | ↓ 0.62% |
Total Liabilities | 2.7B | ↑ 23.58% |
FY23 | Y/Y Change | |
---|---|---|
Total Assets | 3.3B | ↑ 4.35% |
Total Liabilities | 2.4B | ↓ 12.33% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 3.1B | ↓ 2.19% |
Total Liabilities | 2.3B | ↓ 14.45% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 3.1B | ↑ 2.16% |
Total Liabilities | 2.4B | ↑ 1.6% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 3.1B | ↓ 0.52% |
Total Liabilities | 2.3B | ↓ 1.64% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 3.3B | ↑ 4.98% |
Total Liabilities | 2.4B | ↑ 2.55% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Total Assets | 3.2B | ↓ 1.23% |
Total Liabilities | 2.3B | ↓ 5.91% |
Q2 FY24 | Q/Q Change | |
---|---|---|
Total Assets | 3.4B | ↑ 6.2% |
Total Liabilities | 2.3B | ↑ 3.71% |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -388.7M | ↑ 67.53% |
Investing Cash Flow | -370.5M | ↑ 107.19% |
Financing Cash Flow | 530.2M | ↓ 40.3% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -456.5M | ↑ 17.45% |
Investing Cash Flow | 286.7M | ↓ 177.39% |
Financing Cash Flow | 642.6M | ↑ 21.2% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 107.5M | ↓ 123.54% |
Investing Cash Flow | -121.7M | ↓ 142.45% |
Financing Cash Flow | 682.3M | ↑ 6.19% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -443.2M | ↓ 512.38% |
Investing Cash Flow | 495.4M | ↓ 507.01% |
Financing Cash Flow | 561.6M | ↓ 17.7% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -325.3M | ↓ 26.59% |
Investing Cash Flow | -1.0B | ↓ 311.32% |
Financing Cash Flow | 232.5M | ↓ 58.6% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -209.4M | ↑ 126.64% |
Investing Cash Flow | 12.5M | ↑ 27.52% |
Financing Cash Flow | 101.8M | ↑ 847.02% |
Sell
Neutral
Buy
Sarepta Therapeutics, Inc. is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
![]() Sarepta Therapeutics, Inc. | -7.95% | 6.74% | 5.67% | 64.08% | 48.8% |
![]() Regeneron Pharmaceuticals, Inc. | 5.97% | 16.25% | 37.11% | 69.18% | 305.56% |
![]() Novo Nordisk A/s | 9.99% | -3.52% | 34.24% | 158.74% | 417.73% |
![]() Alnylam Pharmaceuticals, Inc. | -5.15% | 64.67% | 22.72% | 31.08% | 198.44% |
![]() Vertex Pharmaceuticals Incorporated | 0.45% | 14.0% | 36.06% | 143.5% | 167.72% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
![]() Sarepta Therapeutics, Inc. | 178.36 | 178.36 | 159.25 | 1.59 | 0.05 | 0.01 | NA | 11.3 |
![]() Regeneron Pharmaceuticals, Inc. | 29.93 | 29.93 | 1.54 | 45.05 | 0.17 | 0.08 | NA | 261.41 |
![]() Novo Nordisk A/s | 44.01 | 44.01 | 1.98 | 3.44 | 0.89 | 0.23 | 0.01 | 25.24 |
![]() Alnylam Pharmaceuticals, Inc. | NA | NA | -0.49 | -2.55 | -15.01 | 0.02 | NA | -0.02 |
![]() Vertex Pharmaceuticals Incorporated | 32.84 | NA | 0.57 | 0.32 | -0.03 | 0.13 | NA | 57.26 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
![]() Sarepta Therapeutics, Inc. | Buy | $12.8B | 48.8% | 178.36 | 3.14% |
![]() Regeneron Pharmaceuticals, Inc. | Buy | $124.7B | 305.56% | 29.93 | 32.04% |
![]() Novo Nordisk A/s | Buy | $585.3B | 417.73% | 44.01 | 34.84% |
![]() Alnylam Pharmaceuticals, Inc. | Buy | $32.3B | 198.44% | NA | -3.11% |
![]() Vertex Pharmaceuticals Incorporated | Buy | $120.9B | 167.72% | 32.84 | -4.74% |
Insights on Sarepta Therapeutics, Inc.
Revenue is down for the last 2 quarters, 413.46M → 362.93M (in $), with an average decrease of 12.2% per quarter
Netprofit is down for the last 3 quarters, 45.65M → 6.46M (in $), with an average decrease of 51.5% per quarter
In the last 1 year, Regeneron Pharmaceuticals, Inc. has given 37.1% return, outperforming this stock by 31.4%
In the last 3 years, Novo Nordisk A/s has given 69.2% return, outperforming this stock by 5.1%
BlackRock Inc
Vanguard Group Inc
Capital Research & Mgmt Co - Division 3
HHG PLC
venBio Select Advisor LLC
Farallon Capital Management, L.L.C.
sarepta therapeutics is a biopharmaceutical company focused on the discovery and development of unique rna-targeted therapeutics for the treatment of rare, infectious and other diseases. the company is primarily focused on rapidly advancing the development of its potentially disease-modifying dmd drug candidates, including its lead dmd product candidate, eteplirsen, designed to skip exon 51. sarepta is also developing therapeutics for the treatment of infectious diseases, such as drug-resistant bacteria and other rare human diseases. for more information, please visit us at www.sarepta.com.
Organization | Sarepta Therapeutics, Inc. |
Employees | 1314 |
CEO | Mr. Douglas S. Ingram Esq. |
Industry | Health Technology |
Sirius Xm Holdings Inc.
$128.92
-3.63%
Cognizant Technology Solutions Corp.
$128.92
-3.63%
Globalfoundries Inc.
$128.92
-3.63%
Deckers Outdoor Corp.
$128.92
-3.63%
Bxp Inc
$128.92
-3.63%
Realty Income Corporation
$128.92
-3.63%
Gold Shares Spdr
$128.92
-3.63%
Vertiv Holdings Co
$128.92
-3.63%
S&p Dividend Spdr
$128.92
-3.63%